Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.76 USD | +3.58% | -2.84% | -34.15% |
03-11 | AbCellera, Biogen Collaborate to Discover Treatments for Neurological Diseases | MT |
03-11 | AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions | CI |
Evolution of the average Target Price on AbCellera Biologics Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering AbCellera Biologics Inc.
Benchmark Company | |
Stifel Nicolaus | |
KeyBanc Capital Markets | |
Piper Sandler | |
Goldman Sachs | |
Berenberg Bank | |
Credit Suisse | |
Cowen | |
BMO Capital | |
SVB Securities LLC | |
Truist Securities | |
SVB Leerink | |
Benchmark Capital |
EPS Revisions
- Stock Market
- Equities
- ABCL Stock
- Consensus AbCellera Biologics Inc.